Healthy Subjects, Pharmacokinetics of Darexaban and Metabolites
Conditions
Keywords
Pharmacokinetics, darexaban, YM150, rifampicin, Phase 1
Brief summary
The primary objective of this study is to determine the effect of rifampicin on the way the body handles darexaban and its metabolites (drug degradation products). The secondary objective of the study is to evaluate the safety and tolerability of a single dose of darexaban alone and when administered together with rifampicin.
Detailed description
This is an open-label, 1-sequence study in young healthy male subjects to evaluate the effect of multiple daily doses of rifampicin on the PK of darexaban and metabolites after a single dose of darexaban. In addition, safety and tolerability of darexaban administered alone and in combination with rifampicin is evaluated. Eligible subjects are admitted to the clinical unit in the morning of Day -1. Subjects receive a single dose of darexaban on Day 1. Subjects then receive rifampicin once daily (qd) on Days 4-14.On Day 11, the second single dose of darexaban is given in combination with rifampicin.
Interventions
DRUGdarexaban
oral
DRUGRifampicin
oral
Sponsors
Astellas Pharma Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Body Mass Index (BMI) between 18.5-30.0 kg/m2 * Male subjects must be non-fertile, i.e. surgically sterilized or must practice an adequate contraceptive method to prevent pregnancies
Exclusion criteria
* Known or suspected hypersensitivity to darexaban or rifampicin or any components of the formulation used * Any of the liver function tests (i.e. ALT and AST) above the upper limit of normal at repeated measures * Any clinically significant history of any other disease or disorder - gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric or metabolic as judged by the medical investigator * Any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG and clinical laboratory tests * Use of any prescribed or OTC drugs (including vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the Clinical Unit, except for occasional use of paracetamol (up to 3 g/day) * Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampicin) in the 3 months prior to admission to the Clinical Unit * Any use of drugs of abuse, or smoking of more than 10 cigarettes (or equivalent) or more than 21 units (210 g) of alcohol per week within the 3 months prior to study Donation of blood or blood products within 3 months prior to admission to the Clinical Unit * Participation in any clinical study within 3 months or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study, provided that the clinical study did not entail a biological compound with a long terminal half life
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics of darexaban and its metabolites assessed by plasma concentration | Plasma samples are taken until 72 hours after darexaban dosing |
Secondary
| Measure | Time frame |
|---|---|
| Monitoring of safety and tolerability through assessment of vital signs, ECG, clinical safety laboratory and adverse events | 15 days |
Countries
France
Outcome results
None listed